Conclusion
Global developments in the diagnosis and
treatment of thalassaemia have seen vast
improvements in the management of pregnant
women diagnosed with thalassaemia. Normal
pregnancy and birth can be achieved with
collaborative health care and a multidisciplinary
approach to women with thalassaemia. However,
women remain high risk for maternal and
fetal morbidity if not appropriately managed.
Pregnancy outcomes are improved with early
diagnosis, specialist involvement, and follow-up
care of maternal and fetal health. Although
pharmacological treatment is the first line of
therapy in managing symptoms of thalassaemia,
research into the value of complementary
and alternative medicine suggests that
non-pharmacological therapies may provide
cost-effective, low-risk support to women during
pregnancy and birth, with beneficial outcomes
for both maternal and fetal wellbeing.